Biocogniv
Biocogniv, based in Burlington, VT, specializes in AI diagnostics for acute care, focusing on early detection of conditions like sepsis through its Sepsis aiMarker™, which predicts sepsis up to 72 hours in advance.
Company History
Biocogniv, formerly known as Biocogniv Inc, was founded to address critical needs in healthcare diagnostics. The company is headquartered in Burlington, VT, USA, and has been active in the industry since it was part of the S20 batch of Y-Combinator. Its primary aim is to tackle the issue of late diagnosis and intervention in acute care, a significant factor in hospital mortality rates in the United States.
Innovative Healthcare Solutions
Biocogniv focuses on the development of AI diagnostics tailored for acute care. The Sepsis aiMarker™ is one of their prominent innovations, receiving FDA Breakthrough Designation. This tool can predict and detect sepsis up to 72 hours in advance using routine laboratory panels, potentially saving lives by allowing timely intervention. The company's tech leverages routine hospital tests and state-of-the-art AI to identify acute conditions early.
Key Partnerships and Collaborations
Biocogniv collaborates with notable healthcare institutions and organizations to advance its diagnostic capabilities. Key partners include UTMB Health, St. Joseph's General Hospital, Vituity, NIH, and NSF. Through these partnerships, Biocogniv has processed over 16 million patient encounters and 1 billion lab results, enhancing the accuracy and reliability of its AI-powered diagnostics.
Proprietary Platforms and Technologies
Biocogniv's proprietary platforms, including ClinOS™, power a vast scale of real-world evidence. ClinOS™ is a cloud-based platform that links with numerous hospital systems across the US, processing thousands of laboratory tests daily. This extensive data processing capability supports not only the Sepsis aiMarker™ but also other aiMarkers™ in the pipeline, such as those for acute kidney injury and GI bleed.
Impact on Acute Care
Biocogniv's AI diagnostics have significant implications for acute care. The Sepsis aiMarker™ aims to mitigate one of the leading causes of hospital mortality by enabling early detection and intervention. With a focus on delivering actionable insights from routine tests, Biocogniv strives to reduce the number of deaths due to acute conditions by offering predictive and diagnostic tools that can manage patient care more effectively.
